ArticleCancer medicine2022

Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.

Man Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.